印度6至17岁儿童接种13价肺炎球菌结合疫苗的4期安全性研究
结果显示73.9%和57.8%的受试者分别报告局部反应和全身事件,多为轻中度,无与疫苗相关的严重不良事件。结论认为PCV13在该年龄组耐受性良好,支持其安全性特征。
要点
- PCV13在印度6-17岁健康儿童中耐受性良好,安全性可接受。
- 局部反应报告率73.9%,全身事件57.8%,以轻中度为主。
- 无与PCV13相关的严重不良事件,无因不良事件退出或死亡。
核心结论
- PCV13接种在印度6至17岁健康受试者中耐受性良好,具有可接受的安全性特征。
研究设计与样本
- 接种后7天内由照护者每日电子日记记录局部反应和全身事件,至接种后28-42天收集不良事件。
主要发现
- 接种后73.9%的受试者报告局部反应,57.8%报告全身事件。
- 大多数反应性事件为轻中度,最常见的局部反应为注射部位疼痛,最常见的全身事件为疲劳。
- 6名受试者报告7例不良事件,均被认为与PCV13无关;1名受试者报告严重不良事件(急性肝炎),被认为与PCV13无关并最终缓解。
- 无受试者因不良事件退出,无死亡报告。
临床怎么用
- 为印度6至17岁儿童接种PCV13预防肺炎球菌疾病提供安全性证据支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The 13-valent pneumococcal conjugate vaccine (PCV13) was recently approved in India for the prevention of pneumococcal disease in children aged 6 to 17 years based on global data as well as immunogenicity and safety findings from a phase 3 study. The current phase 4 study in India further evaluated the safety profile of PCV13 in this age group to support the positive benefit-risk profile of PCV13. METHODS: Healthy male and female children aged 6 to 17 years in India were administered a single intramuscular injection of PCV13. Through 7 days after PCV13 administration, local reactions and systemic events were recorded daily by caregivers in an electronic diary. Adverse events (AEs) were collected from the provision of informed consent through 28-42 days postvaccination. RESULTS: One hundred subjects enrolled in and completed the study. After PCV13 vaccination, 73.9% and 57.8% of subjects reported local reactions and systemic events, respectively. The majority of reactogenicity events were mild to moderate in severity, with injection site pain and fatigue the most frequently reported local reaction and systemic event, respectively. Six subjects reported 7 AEs, all of which were considered unrelated to PCV13. One subject reported a serious AE (acute hepatitis), which was considered unrelated to PCV13 and ultimately resolved. No subjects withdrew because of AEs, and there were no deaths. CONCLUSION: PCV13 vaccination was well tolerated with an acceptable safety profile in healthy subjects aged 6 to 17 years in India. This work further supports the safety profile of PCV13 for prevention of pneumococcal disease in this age group in India.
引用
- Chhatwal J, Sapru A, Sundaram B, et al. A phase 4 study of the safety of the 13-valent pneumococcal conjugate vaccine in children 6 to 17 years of age in India. Vaccine. 2021. PMID: 34366142. doi:10.1016/j.vaccine.2021.07.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。